Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04880863 · ClinicalTrials.gov registry record · Phase 2

NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by NeoTX Therapeutics.

Completed
Registry status
Phase 2
Development phase
38
Enrollment target
11
Study locations

NCT04880863 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by NeoTX Therapeutics. The registered enrollment target is 38 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 11 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04880863, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by NeoTX Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
38 participants
Enrollment target
11
Study locations

Study Summary

Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP), following Obinutuzumab Pretreatment, on Days -13 and -12. NAP will be administered on Days 1-4 of treatment cycles 1-6, followed by docetaxel on Day 5. Starting cycle 7, NAP at a higher dose will be administered on Day 1 only and docetaxel on Day 2, in 21 days treatment cycles. When NAP is administered as monotherapy and not earlier than cycle 7, NAP will be administered on Day 1 only and cycles will be of 28 days treatment cycle.

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG Obinutuzumab
  • DRUG Docetaxel
  • DRUG NAP (Naptumomab estafenatox)

Study Locations (11)

Texas

  • NeoTX - 10308 - Austin
  • NeoTX - 10309 - Dallas
  • NeoTX - 10312 - El Paso
  • NeoTX - 10310 - Tyler

Arizona

  • NeoTX - 10302 - Scottsdale
  • NeoTX - 10303 - Tucson

Alabama

  • NeoTX - 10307 - Daphne

Colorado

  • NeoTX - 10306 - Lone Tree

Minnesota

  • NeoTX - 10304 - Minneapolis

New Jersey

  • NeoTX - 10100 - Morristown

Virginia

  • NeoTX - 10311 - Fairfax

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2021-10-26
Est. Completion 2024-01-30
Phase Phase 2

Sponsor

NeoTX Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04880863

The ClinicalTrials.gov registry entry for NCT04880863 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The listed sponsor is NeoTX Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Obinutuzumab is the first listed.

NCT04880863 reports 11 study locations spanning 7 distinct geographic areas - top geographies include Texas, Arizona, Alabama.

Frequently Asked Questions

What is clinical trial NCT04880863 about?

NCT04880863 is a clinical study titled "NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC". Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP), following Obinutuzumab Pretreatment, on Days -13 and -12. NAP will be administered on Days 1-4 of treatment cycles 1-6, followed by docetaxel on Day 5. Starting cycle 7, NAP at a higher dose will be administered on Day 1 only an...

What is the current status of trial NCT04880863?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2021-10-26. Estimated completion is 2024-01-30.

What conditions does trial NCT04880863 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT04880863?

The interventions under investigation include: Obinutuzumab (DRUG), Docetaxel (DRUG), NAP (Naptumomab estafenatox) (DRUG).

Who is sponsoring clinical trial NCT04880863?

This trial is sponsored by NeoTX Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04880863 being conducted?

This trial has 11 study locations across Alabama, Arizona, Colorado, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.